the international society for gastrointestinal hereditary tumoursEstimated Valuation
£2.1k
Pomanda estimates the enterprise value of THE INTERNATIONAL SOCIETY FOR GASTROINTESTINAL HEREDITARY TUMOURS at £2.1k based on a Turnover of £4.6k and 0.47x industry multiple (adjusted for size and gross margin).
the international society for gastrointestinal hereditary tumoursEstimated Valuation
£0
Pomanda estimates the enterprise value of THE INTERNATIONAL SOCIETY FOR GASTROINTESTINAL HEREDITARY TUMOURS at £0 based on an EBITDA of £-40.1k and a 3.55x industry multiple (adjusted for size and gross margin).
the international society for gastrointestinal hereditary tumoursEstimated Valuation
£48.1k
Pomanda estimates the enterprise value of THE INTERNATIONAL SOCIETY FOR GASTROINTESTINAL HEREDITARY TUMOURS at £48.1k based on Net Assets of £21.6k and 2.23x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
The International Society For Gastrointestinal Hereditary TumoursOverview
The International Society For Gastrointestinal Hereditary Tumours is a live company located in acton lane, london, NW10 7NS with a Companies House number of 07358100. It operates in the other human health activities sector, SIC Code 86900. Founded in August 2010, it's largest shareholder is
unknown.
The International Society For Gastrointestinal Hereditary Tumours is a established,
micro sized company, Pomanda has estimated its turnover at
£4.6k with
declining
growth in recent years.
The International Society For Gastrointestinal Hereditary Tumours Health Check
Pomanda's financial health check has awarded The International Society For Gastrointestinal Hereditary Tumours a 2.5 rating. We use a traffic light system to show it exceeds the industry average on 2 measures and has 5 areas for improvement. Company Health Check FAQs
Health Rating2.5out of 5
2 Strong
1 Regular
5 Weak
Size
annual sales of £4.6k, make it smaller than the average company (£646.6k)
£4.6k - The International Society For Gastrointestinal Hereditary Tumours
£646.6k - Industry AVG
Growth
3 year (CAGR) sales growth of -3%, show it is growing at a slower rate (5.8%)
-3% - The International Society For Gastrointestinal Hereditary Tumours
5.8% - Industry AVG
Production
with a gross margin of 39%, this company has a comparable cost of product (39%)
39% - The International Society For Gastrointestinal Hereditary Tumours
39% - Industry AVG
Profitability
an operating margin of -879.3% make it less profitable than the average company (5.7%)
-879.3% - The International Society For Gastrointestinal Hereditary Tumours
5.7% - Industry AVG
Employees
with 1 employees, this is below the industry average (16)
1 - The International Society For Gastrointestinal Hereditary Tumours
16 - Industry AVG
Pay Structure
There is insufficient data available for this Key Performance Indicator!
- - The International Society For Gastrointestinal Hereditary Tumours
- - Industry AVG
Efficiency
resulting in sales per employee of £4.6k, this is less efficient (£48.1k)
£4.6k - The International Society For Gastrointestinal Hereditary Tumours
£48.1k - Industry AVG
Debtor Days
There is insufficient data available for this Key Performance Indicator!
- - The International Society For Gastrointestinal Hereditary Tumours
- - Industry AVG
Creditor Days
There is insufficient data available for this Key Performance Indicator!
- - The International Society For Gastrointestinal Hereditary Tumours
- - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- - The International Society For Gastrointestinal Hereditary Tumours
- - Industry AVG
Cash Balance
has cash to cover current liabilities
for 811 weeks, this is more cash available to meet short term requirements (113 weeks)
811 weeks - The International Society For Gastrointestinal Hereditary Tumours
113 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 6%, this is a lower level of debt than the average (26.5%)
6% - The International Society For Gastrointestinal Hereditary Tumours
26.5% - Industry AVG
THE INTERNATIONAL SOCIETY FOR GASTROINTESTINAL HEREDITARY TUMOURS financials
EXPORT
The International Society For Gastrointestinal Hereditary Tumours's latest turnover from August 2023 is £4.6 thousand and the company has net assets of £21.6 thousand. According to their latest financial statements, we estimate that The International Society For Gastrointestinal Hereditary Tumours has 1 employee and maintains cash reserves of £21.5 thousand as reported in the balance sheet.
Data source:Companies House, Pomanda Estimates
Aug 2023
Aug 2022
Aug 2021
Aug 2020
Aug 2019
Aug 2018
Aug 2017
Aug 2016
Aug 2015
Aug 2014
Aug 2013
Aug 2012
Aug 2011
Turnover
4,565
14,862
5,037
4,961
22,692
7,441
28,724
7,868
19,105
7,591
22,979
3,190
43,493
Other Income Or Grants
Cost Of Sales
2,784
9,240
3,359
3,167
14,520
4,812
17,658
4,875
11,997
4,733
14,003
1,849
24,836
Gross Profit
1,781
5,622
1,678
1,794
8,172
2,629
11,066
2,993
7,108
2,858
8,976
1,341
18,657
Admin Expenses
41,923
-3,186
-1,024
3,467
-6,167
252
-1,356
6,569
-439
4,559
-5,259
8,454
-10,746
Operating Profit
-40,142
8,808
2,702
-1,673
14,339
2,377
12,422
-3,576
7,547
-1,701
14,235
-7,113
29,403
Interest Payable
304
541
352
Interest Receivable
Pre-Tax Profit
-37,981
7,938
2,230
-1,622
11,893
2,159
10,128
-3,502
6,151
-1,568
11,051
-7,066
21,758
Tax
Profit After Tax
-37,981
7,938
2,230
-1,622
11,893
2,159
10,128
-3,502
6,151
-1,568
11,051
-7,066
21,758
Dividends Paid
Retained Profit
-37,981
7,938
2,230
-1,622
11,893
2,159
10,128
-3,502
6,151
-1,568
11,051
-7,066
21,758
Employee Costs
22,632
21,720
21,459
20,499
21,401
21,497
21,483
21,148
42,194
Number Of Employees
1
1
1
1
1
1
1
1
1
1
1
1
2
EBITDA*
-40,142
8,808
2,702
-1,673
14,830
2,868
12,913
-3,576
7,547
-1,701
14,235
-7,113
29,403
* Earnings Before Interest, Tax, Depreciation and Amortisation
Aug 2023
Aug 2022
Aug 2021
Aug 2020
Aug 2019
Aug 2018
Aug 2017
Aug 2016
Aug 2015
Aug 2014
Aug 2013
Aug 2012
Aug 2011
Tangible Assets
491
982
Intangible Assets
Investments & Other
Debtors (Due After 1 year)
Total Fixed Assets
491
982
Stock & work in progress
Trade Debtors
Group Debtors
Misc Debtors
1,420
100
358
312
312
312
312
88
24,157
Cash
21,529
60,800
52,607
50,390
52,012
39,629
37,219
28,054
31,526
25,375
27,663
18,924
misc current assets
total current assets
22,949
60,900
52,965
50,702
52,324
39,941
37,531
28,054
31,526
25,375
27,663
19,012
24,157
total assets
22,949
60,900
52,965
50,702
52,324
40,432
38,513
28,054
31,526
25,375
27,663
19,012
24,157
Bank overdraft
Bank loan
Trade Creditors
Group/Directors Accounts
other short term finances
hp & lease commitments
other current liabilities
1,380
1,350
1,353
1,320
1,320
1,321
1,561
1,230
1,200
1,200
1,920
4,320
2,400
total current liabilities
1,380
1,350
1,353
1,320
1,320
1,321
1,561
1,230
1,200
1,200
1,920
4,320
2,400
loans
hp & lease commitments
Accruals and Deferred Income
other liabilities
provisions
total long term liabilities
total liabilities
1,380
1,350
1,353
1,320
1,320
1,321
1,561
1,230
1,200
1,200
1,920
4,320
2,400
net assets
21,569
59,550
51,612
49,382
51,004
39,111
36,952
26,824
30,326
24,175
25,743
14,692
21,757
total shareholders funds
21,569
59,550
51,612
49,382
51,004
39,111
36,952
26,824
30,326
24,175
25,743
14,692
21,757
Aug 2023
Aug 2022
Aug 2021
Aug 2020
Aug 2019
Aug 2018
Aug 2017
Aug 2016
Aug 2015
Aug 2014
Aug 2013
Aug 2012
Aug 2011
Operating Activities
Operating Profit
-40,142
8,808
2,702
-1,673
14,339
2,377
12,422
-3,576
7,547
-1,701
14,235
-7,113
29,403
Depreciation
491
491
491
Amortisation
Tax
Stock
Debtors
1,320
-258
46
312
-88
-24,069
24,157
Creditors
Accruals and Deferred Income
30
-3
33
-1
-240
331
30
-720
-2,400
1,920
2,400
Deferred Taxes & Provisions
Cash flow from operations
-41,432
9,063
2,689
-1,673
14,829
2,628
12,932
-3,546
7,547
-2,421
11,923
18,876
7,646
Investing Activities
capital expenditure
-1,473
Change in Investments
cash flow from investments
-1,473
Financing Activities
Bank loans
Group/Directors Accounts
Other Short Term Loans
Long term loans
Hire Purchase and Lease Commitments
other long term liabilities
share issue
1
-1
interest
-304
-541
-352
cash flow from financing
-304
-541
-352
1
-1
cash and cash equivalents
cash
-39,271
8,193
2,217
-1,622
12,383
2,410
9,165
-3,472
6,151
-2,288
8,739
18,924
overdraft
change in cash
-39,271
8,193
2,217
-1,622
12,383
2,410
9,165
-3,472
6,151
-2,288
8,739
18,924
the international society for gastrointestinal hereditary tumours Credit Report and Business Information
Very Low Risk70 - 100
Low Risk50 - 70
Moderate Risk30 - 50
High Risk20 - 30
Very High Risk0 - 20
Get a comprehensive credit check for the international society for gastrointestinal hereditary tumours. Get real-time insights into the international society for gastrointestinal hereditary tumours's credit score, group structure and payment trends.
The International Society For Gastrointestinal Hereditary Tumours Competitor Analysis
Perform a competitor analysis for the international society for gastrointestinal hereditary tumours by selecting its closest rivals, whether from the HUMAN HEALTH AND SOCIAL WORK ACTIVITIES sector, other micro companies, companies in NW10 area or any other competitors across 12 key performance metrics.
the international society for gastrointestinal hereditary tumours Ownership
THE INTERNATIONAL SOCIETY FOR GASTROINTESTINAL HEREDITARY TUMOURS group structure
The International Society For Gastrointestinal Hereditary Tumours has no subsidiary companies.
Ultimate parent company
THE INTERNATIONAL SOCIETY FOR GASTROINTESTINAL HEREDITARY TUMOURS
07358100
THE INTERNATIONAL SOCIETY FOR GASTROINTESTINAL HEREDITARY TUMOURS Shareholders
The sole shareholder of The International Society For Gastrointestinal Hereditary Tumours is -.
-
-
the international society for gastrointestinal hereditary tumours directors
The International Society For Gastrointestinal Hereditary Tumours currently has 12 directors.
The longest serving directors include
Prof Susan Clark (Nov 2010) and
Dr Andrew Latchford (Jul 2017).
the international society for gastrointestinal hereditary tumours company details
company number
07358100
Type
Private Limited by guarantee without Share Capital Exempt from using Limited
industry
86900 - Other human health activities
incorporation date
August 2010
age
15
incorporated
UK
ultimate parent company
None
accounts
Total Exemption Full
last accounts submitted
August 2023
previous names
N/A
accountant
MELINEK FINE LLP
auditor
-
address
the st marks centre for familial, st marks hospital central middle, acton lane, london, NW10 7NS
Bank
-
Legal Advisor
-
the international society for gastrointestinal hereditary tumours Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We did not find charges/mortgages relating to the international society for gastrointestinal hereditary tumours.
the international society for gastrointestinal hereditary tumours Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for THE INTERNATIONAL SOCIETY FOR GASTROINTESTINAL HEREDITARY TUMOURS. This can take several minutes, an email will notify you when this has completed.
the international society for gastrointestinal hereditary tumoursCompanies House Filings - See Documents
